Pfizer in 2005
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTA120
Case Length : 15 Pages
Period : 1849-2005
Organization : -
Pub Date : 2005
Teaching Note :Not Available
Countries : USA
Industry : Pharmaceuticals
To download Pfizer in 2005 case study (Case Code: BSTA120) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs.
300 + Rs. 25 for Shipping & Handling Charges
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Excerpts Contd...
Acquisitions
|
Warner Lambert
Pfizer had largely believed in organic growth till the mid-90s. However when Warner Lambert, the pharmaceutical company that owned the patent on atorvastatin calcium (Lipitor) announced its intention to merge with American Home Products (AHP),
Pfizer launched a hostile take over bid. Pfizer sensed a big opportunity in 'Lipitor'...
Pharmacia
Pfizer typically struck alliances to generate more revenues. Among the drugs, which Pfizer brought into the stable through alliances were Tahor with Parke-Davis, Celebrex with Pharmacia and Aricept with Eisai...
|
|
Growing Concerns
As 2005 got underway, Pfizer faced some major concerns. The sales of some its blockbuster (any drug with sales of $1 billion or more) drugs such as Viagra and Lipitor were decreasing. Competition from other drug makers was increasing, while patent expiration of important drugs loomed large on the horizon...
|
|
The Road Ahead
A combination of strategies had helped Pfizer climb to the top of the pack in the global pharmaceutical market. Pfizer had acquired leading competitors, developed blockbuster products and taken advantage of favorable regulations, often after lobbying for them...
Exhibits
Exhibit 1: Pfizer - Key Products
Exhibit 2: Pfizer - Product Pipeline
Exhibit 3: Pfizer - Revenue by Segment
Exhibit 4: Pfizer - Business Segment Revenues
Exhibit 5: Pfizer - Financial Summary |
|
|
